Get the Stockscreener App
26.54
3.11%
0.80
After Hours:
26.65
0.11
+0.41%
Moderna Inc stock is traded at $26.54, with a volume of 7.99M.
It is up +3.11% in the last 24 hours and down -18.74% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$25.74
Open:
$26.5
24h Volume:
7.99M
Relative Volume:
0.74
Market Cap:
$9.74B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-4.5601
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
+5.36%
1M Performance:
-18.74%
6M Performance:
-50.29%
1Y Performance:
-75.40%
1-Day Range:
$26.45
$27.88
1-Week Range:
$23.30
$27.88
52-Week Range:
$23.15
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
26.54 | 9.74B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.42 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.85 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.65 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.97 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Novavax: New COVID-19 Vaccine on Track for FDA Approval - Inc.com
SK bioscience wins patent case against Moderna in South Korea - Social News XYZ
TD Cowen Adjusts Moderna Price Target to $30 From $35, Maintains Hold Rating - marketscreener.com
Vaccine-wary Slovak PM pauses COVID-19 shot purchases pending review - marketscreener.com
Novavax says its COVID-19 shot is on track for full FDA approval after delay - Value The Markets
Moderna (NASDAQ:MRNA) Given Market Perform Rating at William Blair - MarketBeat
Canada Pension Plan Investment Board Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
More Downside For Moderna Before The Breakthrough (NASDAQ:MRNA) - Seeking Alpha
Moderna Can't Buy Time To Defend COVID Vax UPC Claim - Law360
Press Release Distribution & PR Platform - ACCESS Newswire
Guggenheim Capital LLC Cuts Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Altshuler Shaham Ltd Boosts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What to Expect From Moderna's Q1 2025 Earnings Report - Nasdaq
Scotia Capital Inc. Has $284,000 Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Brokerages Set Moderna, Inc. (NASDAQ:MRNA) Target Price at $58.70 - MarketBeat
Bridgewater Associates LP Makes New Investment in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Wolfe Research Adjusts Moderna Price Target to $20 From $25, Keeps Underperform Rating - marketscreener.com
What To Expect From Moderna's Q1 2025 Earnings Report - Barchart.com
Preventive Vaccines Market Forecast 2025-2032- Growth - openPR.com
Where Will Moderna Be in 5 Years? - Yahoo Finance
Advisory Services Network LLC Purchases 16,555 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Q1 Earnings Forecast for Moderna Issued By Leerink Partnrs - MarketBeat
Lobbying Update: $60,000 of MODERNA INC. lobbying was just disclosed - Nasdaq
Russell Investments Group Ltd. Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Bank of Montreal Can Trims Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
The Gutierrez Co. Sued Over Mold, Water Damage at Moderna Site — Boston Business Journal - Boston Real Estate Times
Moderna sues construction firm claiming leaks, mold at new drug plant - NBC Boston
Water leaks, mold plague Moderna's new manufacturing site, lawsuit claims - The Business Journals
Quinn Opportunity Partners LLC Purchases Shares of 16,500 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Benzinga
Invesco Ltd. Acquires 979,858 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Says New Drug Plant Riddled With Defects, Mold - Law360
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Legal & General Group Plc - MarketBeat
Moderna (MRNA) Leads Healthcare Short Interest in March - GuruFocus
Lansdowne Partners UK LLP Acquires New Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Neuberger Berman Group LLC Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Bloom Energy, Rogers, 3D Systems, Moderna, and EchoStar Stocks Trade Down, What You Need To Know - The Globe and Mail
Moderna permitted to start commercial mRNA vaccine manufacture in UK - The Pharma Letter
Leerink Partners Adjusts Moderna Price Target to $23 From $27, Maintains Underperform Rating - marketscreener.com
Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan
MRNA Based Vaccines and Therapeutics Therapeutics Market Size - openPR.com
Renaissance Technologies LLC Grows Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
APG Asset Management N.V. Buys 203,792 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Special Assistant Høeg’s Vaccine Concerns On Display At ACIP - insights.citeline.com
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Shelton Capital Management - MarketBeat
Stocks Edge Up On Strong Bank Earnings, Netflix Soars, Dollar Rebounds: What's Driving Markets Tuesday? - Benzinga
Goldman Sachs Adjusts Moderna's Price Target to $35 From $49, Keeps Neutral Rating - MarketScreener
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
21.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):